Made for the UK. Informed by evidence.Our editorial promise
INTERNATIONAL CONTEXT FOR UK READERS

Obesity care in North America

US and Canadian treatment news often reaches UK readers before the local context does. The United States, Canada and Mexico have their own regulators and payment arrangements. Their approvals, programme prices and insurance benefits do not establish UK access. These pages explain the distinctions behind the headlines.

Match the comparison to your plan

US programme and insurer rules, Canadian public drug-plan decisions and Mexican institutional coverage require local checks. A national approval or health-technology recommendation does not establish an individual's benefit.

Read international prices in context

A US cash price, a Canadian dispensing charge and a UK private-care package can describe different services and quantities. Currency conversion cannot make them equivalent. Our practical provider and price comparisons focus on UK care.

Explore the country guides

3 guides

United States ↗

US access depends on the FDA-approved product and indication, the prescriber's assessment and the payment route. The 2026 Medicare GLP-1 Bridge makes older blanket statements about Medicare weight-management access incomplete.

Read the country guide →

Canada ↗

Health Canada authorisation establishes a medicine's regulatory status. Provincial or other public drug-plan decisions and private benefits determine payment. A national reimbursement recommendation does not by itself provide coverage across Canada.

Read the country guide →

Mexico ↗

Mexico's COFEPRIS records are the starting point for checking a product's registration. Registration, a clinic's ability to supply it and payment through a particular health institution or insurer should be verified separately.

Read the country guide →